Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Venetoclax.
- Who it may be relevant to
- Registry conditions: Acute Myeloid Leukemia (AML). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multicenter, Open-label, Prospective, Randomized Controlled Study to Optimize the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease
Overview
A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease
Detailed description
This study is a randomized controlled, prospective clinical trial, with the leading unit being the First Hospital of Jilin University. It aims to screen patients with a suboptimal response to chemotherapy based on early peripheral blood minimal residual disease (MRD) levels, and explore the efficacy and safety of adding venetoclax. A total of 70 subjects are expected to be enrolled, with 35 subjects each in the experimental group and the control group. The study will collect data on subjects' demographics, other baseline characteristics, medication usage, prognosis, etc. Statistical analysis will be performed on the collected data to compare efficacy indicators.
Interventions
- Drug Venetoclax
Patients identified with a suboptimal response to chemotherapy based on minimal residual disease (MRD) levels in peripheral blood on Day 6 will initiate venetoclax therapy added on Day 8, administered for 7 days.
Primary outcome measures
- Modified Composite Complete Response Rate（mCRc） [Time frame: Through study completion, an average of 1 year]
Secondary outcome measures (3)
- Overall Survival (OS) [Time frame: From date of index treatment to death, disease progression, or end of study, whichever came first, assessed up to 48 months.]
- MRD Negative Conversion Rate [Time frame: Through study completion, an average of 1 year]
- Relapse-Free Survival(RFS) [Time frame: From date of index treatment to death, disease progression, or end of study, whichever came first, assessed up to 48 months.]
Eligibility criteria
Inclusion criteria
- Newly diagnosed AML patients confirmed by bone marrow morphology and immunophenotyping.
- Complete MICM (Morphology, Immunophenotyping, Cytogenetics, Molecular genetics) work-up.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Day 6 Peripheral Blood Blast Percentage (D6PBBP) ≥ 1%.
- Renal function with creatinine clearance ≥ 50 mL/min (calculated using the Cockcroft-Gault formula or measured by 24-hour urine collection).
- Liver function with Aspartate Aminotransferase (AST) ≤ 2.5 × ULN\*; Alanine Aminotransferase (ALT) ≤ 2.5 × ULN\*; Total bilirubin ≤ 1.5 × ULN\* (\*Unless considered due to leukemia infiltration).
- Patients deemed suitable to receive DA/IA therapy by the investigator.
- Signed informed consent form. -
Exclusion criteria
- Acute promyelocytic leukemia (APL).
- Mixed phenotype acute leukemia (MPAL).
- AML patients with known central nervous system (CNS) involvement.
- Presence of extramedullary disease (EMD).
- Significant hepatic or renal dysfunction exceeding the inclusion criteria limits.
- Severe cardiac disease, including congestive heart failure, myocardial infarction, or cardiac dysfunction.
- Concurrent active malignancy of other organ systems (patients with a history of cured malignancy may be eligible).
- Active tuberculosis or HIV-positive patients.
- Concurrent other hematological disorders.
- Pregnant or lactating women.
- Inability to comprehend or comply with the study protocol.
- Hypersensitivity to any component of the drugs involved in the protocol.
- Inability to take oral medication or patients with malabsorption syndrome.
- Uncontrolled systemic infection.
- Prior venetoclax treatment and/or current participation in any other study involving investigational agents.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- The First Hospital of Jilin University — Changchun
Identifiers
NCT: NCT07023588 · 2025-HS-002